Martinez Bueno A, Molina MA, Fielding A, et al. Disruptive mutations in TP53 associate with survival benefit in a PARPi trial in ovarian cancer. ESMO 2017, abstract LBA42.
Verhoogd risico op kanker bij kinderen met IBD
jun 2020 | IBD, Maag-darm-leveroncologie